Yahoo
NasdaqCM - Delayed Quote USD

Cingulate Inc. (CING)

4.9800 -0.2100 (-4.05%)
At close: October 30 at 4:00:01 PM EDT
Chart Range Bar
Loading chart for CING
  • Previous Close 5.1900
  • Open 5.0400
  • Bid 3.4800 x 200
  • Ask 4.6800 x 100
  • Day's Range 4.8400 - 5.1000
  • 52 Week Range 3.1600 - 11.8900
  • Volume 76,642
  • Avg. Volume 121,832
  • Market Cap (intraday) 72.418M
  • Beta (5Y Monthly) -0.88
  • PE Ratio (TTM) --
  • EPS (TTM) -3.5100
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 21.20

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

www.cingulate.com

14

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CING
14.75%
S&P 500 (^GSPC)
10.73%

1-Year Return

CING
37.95%
S&P 500 (^GSPC)
11.11%

3-Year Return

CING
95.17%
S&P 500 (^GSPC)
81.91%

5-Year Return

CING
99.59%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -9.31M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-8M
-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

8.00
21.20 Average
4.9800 Current
44.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/24/2026
Analyst Roth Capital
Rating Action Reiterates
Rating Buy
Price Action Lowers
Price Target 10 -> 9

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -66.94%

  • Return on Equity (ttm)

    -198.74%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -28.81M

  • Diluted EPS (ttm)

    -3.5100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.4M

  • Total Debt/Equity (mrq)

    26.81%

  • Levered Free Cash Flow (ttm)

    -12.84M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: